Eagle Pharmaceuticals Management
Management criteria checks 3/4
Eagle Pharmaceuticals' CEO is Mike Graves, appointed in Jan 2023, has a tenure of 1.92 years. directly owns 0.08% of the company’s shares, worth $5.70K. The average tenure of the management team and the board of directors is 2.4 years and 8.1 years respectively.
Key information
Mike Graves
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.9yrs |
| CEO ownership | 0.08% |
| Management average tenure | 2.4yrs |
| Board average tenure | 8.1yrs |
Recent management updates
Recent updates
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?
Sep 21
Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
Jul 13Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly
Jun 21These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Oct 27Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia
Oct 12Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose
Sep 27Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court
Aug 18Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be
Aug 15Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M
Aug 09These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Jul 06Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price
Apr 29CEO
Mike Graves (61 yo)
1.9yrs
Tenure
US$391,026
Compensation
Mr. Michael Graves, also known as Mike, is Interim Principal Executive Officer of Eagle Pharmaceuticals, Inc. from 2023. He had been the Independent Chairman of Eagle Pharmaceuticals Inc. since June 2016 u...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim Principal Executive Officer & Executive Chairman of the Board | 1.9yrs | US$391.03k | 0.080% $ 5.7k | |
| CFO and Principal Financial & Accounting Officer | less than a year | no data | no data | |
| Executive VP | 7.6yrs | no data | no data | |
| Senior Vice President of Clinical Drug Development | 4.1yrs | no data | no data | |
| Senior Vice President of Pharmaceutical Development | 4.1yrs | no data | no data | |
| Senior VP & Head of Commercial | 2.4yrs | no data | no data | |
| Executive Vice President of Oncology Business Development | 1.9yrs | no data | no data |
2.4yrs
Average Tenure
53yo
Average Age
Experienced Management: EGRX's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim Principal Executive Officer & Executive Chairman of the Board | 11.1yrs | US$391.03k | 0.080% $ 5.7k | |
| Director | 17.8yrs | US$331.03k | 0.21% $ 15.1k | |
| Independent Director | 7.8yrs | US$312.28k | 0.17% $ 12.4k | |
| Independent Director | 8.4yrs | US$324.78k | 0% $ 0 | |
| Lead Independent Director | 5.3yrs | US$308.53k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$308.53k | 0% $ 0 |
8.1yrs
Average Tenure
61.5yo
Average Age
Experienced Board: EGRX's board of directors are considered experienced (8.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:34 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eagle Pharmaceuticals, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Irina Rivkind Koffler | Mizuho Securities USA LLC |
| David Amsellem | Piper Sandler Companies |